Orbital(TM) DPI (Dry Powder Inhaler)

Orbital(TM) DPI is Aptar Pharma's next-generation dry powder inhaler platform engineered for high-dose pulmonary drug delivery. Designed with patient-centric principles, Orbital(TM) enables progressive dispensing from a sealed puck, allowing multiple gentle inhalations to deliver large powder payloads without reloading. This innovative approach minimizes cough reflex and improves comfort, making it ideal for severe respiratory conditions and niche therapies. The device supports cohesive powders, biologics, and drug repurposing, offering flexibility for small molecules and complex formulations. Orbital(TM) integrates digital health connectivity for real-time adherence monitoring and data-driven insights, enhancing trial robustness and patient outcomes. Its propellant-free design aligns with sustainability goals, while ergonomic features ensure ease of use. With global applicability across cystic fibrosis, pulmonary infections, PAH, IPF, and oncology, Orbital(TM) sets a new standard in inhalation.